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Background/Aims: LKB1 is a tumour suppressor gene that is associated with Peutz-Jeghers syndrome
(PJS), a rare autosomal dominant cancer predisposition syndrome. However, germline mutations in the
LKB1 gene are found in only about 60% of patients with PJS, suggesting the existence of a second PJS
gene. The STRAD gene, encoding an LKB1 interacting protein that activates LKB1, which subsequently
leads to polarisation of cells, is an interesting candidate for a second PJS gene and a potential tumour
suppressor gene in sporadic carcinomas.
Methods: The involvement of STRAD in 42 PJS associated tumours (sporadic lung, colon, gastric, and
ovarian adenocarcinomas) was studied using loss of heterozygosity (LOH) analysis of eight microsatellite
markers on chromosome 17, including TP53, BRCA1, and STRAD markers.
Results: Loss of the marker near the STRAD locus was seen in 13 of 29 informative cases, including all
gastric adenocarcinomas. Specific LOH of the STRAD marker was found in four of 29 informative cases.
For these patients all exons and exon–intron boundaries of the STRAD gene were sequenced, but no
somatic mutations were identified. Furthermore, no germline STRAD mutations were found in 10 patients
with PJS and family members without LKB1 germline mutation.
Conclusions: Despite the frequent occurrence of LOH in the STRAD region, these results indicate that
inactivation of the STRAD gene is not essential in the sporadic adenocarcinomas studied, although it is
possible that STRAD may be inactivated in different ways. In addition, no evidence was found for the
hypothesis that STRAD is a second PJS susceptibility gene.
P
eutz-Jeghers Syndrome (PJS) is a rare autosomal
dominant disorder characterised by hamartomatous
polyposis and mucocutaneous melanin pigmentation.1 2
Patients have an 18 times higher relative risk of developing
cancer at several sites,3 with the highest risk of developing
cancers in the colon, breast, pancreas, stomach, and ovary.4 5
Hemminki et al linked PJS to a locus on chromosome 19p13.3
where later the LKB1 gene (serine/threonine kinase 11) was
identified.6 LKB1 has been postulated as a tumour suppressor
gene; however, its exact role has not been clarified yet, but
nearly all germline mutations of LKB1 lead to loss or
impairment of the kinase activity of the protein. Loss of
LKB1 has been studied in a variety of sporadic tumours, but
so far few losses have been described except for lung
adenocarcinomas, where approximately one third of the
patients shows inactivation of LKB1,7 and to a lesser extent in
pancreatic (4%) and biliary (6%) cancers.8 Somatic mutations
of LKB1 have also been reported in malignant melanoma
(11%).9
‘‘Because of the essential function of STRAD in activating
LKB1 and inducing cell polarity, STRAD may also function
as a tumour suppressor gene’’
Several studies have been aimed at elucidating the
function of LKB1. It has been implicated in p53 mediated
apoptosis,10 control of cell cycle arrest,11 Wnt signalling,12 13
transforming growth factor b signalling,14 energy metabo-
lism,15 and cell polarity.16 Baas et al identified STRAD (STE 20
related adapter) as an LKB1 interactor using yeast two hybrid
analysis.17 Upon STRAD expression, LKB1 was activated and
translocated from the nucleus to the cytoplasm, resulting in
complete polarisation of cultured intestinal epithelial cells.
Because of the essential function of STRAD in activating
LKB1 and inducing cell polarity, STRAD may also function as
a tumour suppressor gene.
Although defects in LKB1 were identified as causative for
PJS, mutations in LKB1 have been detected only in about 60%
of patients,18 leaving the underlying gene defect of the
syndrome unclear in the remaining patients. It is possible
that LKB1 mutations have been missed because of short-
comings in the techniques used, but this is not likely to
explain the relatively high proportion of patients without a
germline LKB1 mutation. A second disease locus has been
proposed at chromosome segment 19q13.4, the distal region
of 1p, and on chromosome 6.19–21 Several genes located at
19q13.4 have been excluded as a second PJS gene, in addition
to LIP1 (LKB1 interacting protein 1).22 As a result of its
interaction with LKB1 and its essential role in the activation
of LKB1, STRAD is an interesting candidate for a second PJS
susceptibility gene, or it might be an effector gene determin-
ing the possible Peutz-Jeghers phenotype.
In our study the direct involvement of STRAD, located at
17q23.3, in sporadic adenocarcinomas was studied using loss
of heterozygosity (LOH) analysis of chromosome 17, in
combination with mutation analysis. In addition, sequence
analysis of STRAD was performed for 10 patients with PJS
and their family members without an identified LKB1
germline mutation.
MATERIALS AND METHODS
Patient material
Our research was carried out in accordance with the ethical
guidelines of the research review committee of the Academic
Medical Centre, Amsterdam, the Netherlands.
Abbreviations: IHC, immunohistochemistry; LOH, loss of
heterozygosity; PJS, Peutz-Jeghers syndrome
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A study population of 42 sporadic adenocarcinomas
consisting of eight ovarian adenocarcinomas, 10 cardia
adenocarcinomas, 12 sigmoid adenocarcinomas, and 12 lung
adenocarcinomas was selected from the pathology archives of
the Academic Medical Centre (Amsterdam, the Netherlands).
Formalin fixed, paraffin wax embedded tissue was used, and
for each case non-neoplastic tissue was obtained from a
tumour free lymph node or, when not available, from normal
tissue.
Cell pellets from five lymphoblast cell lines from three
patients with PJS and both parents of another patient with
PJS (as a result of too little tissue from the patient) without
known LKB1 germline mutations from the Erasmus
University (Rotterdam, the Netherlands), in addition to
genomic DNA from five patients with PJS from three
families without LKB1 germline mutations from the Free
University (Amsterdam, the Netherlands), were available
from a study population of patients with PJS fulfilling the
clinical criteria.
Microdissection and DNA isolation
Tumour tissue was microdissected from dewaxed haemat-
oxylin stained 5 mm tissue sections. The percentage of
tumour cells ranged from 70% to 90%. DNA was isolated
using the PUREGENE DNA isolation kit (Gentra Systems,
Minneapolis, Minnesota, USA) according to the manufac-
turer’s protocol. DNA concentrations were measured using
the PicoGreen double stranded DNA Quantitation kit
(Molecular Probes, Leiden, the Netherlands).
Genomic DNA from cell pellets was isolated by proteinase
K/sodium dodecyl sulfate precipitation, followed by phenol/
chloroform extraction and ethanol precipitation.
Loss of heterozygosity
Eight markers were used for LOH analysis, two on chromo-
some 17p13.1 around the TP53 locus (markers TP53 and
p53Alu) and six on the 17q arm: D17S791, D17S1795,
D17S795, markers D17S250 and D17S855 around BRCA1,
and marker D17S944 near STRAD. Primer sequences of these
markers can be found on The Genome Database website
(www.gdb.org). The primer sequence of p53Alu is: forward,
59-GAATCCGGGAGGAGGTTG and reverse, 59-
AACAGCTCCTTTAATGGCAG-39. The forward primers were
FAM (6-carboxy-fluorescein) or TET (6-carboxy-4,7,29,79-
tetrachlorofluorescein) labelled.
The polymerase chain reaction was performed using 10mM
dNTPs, 1.5mM MgCl2, 0.5mM of both primers, 0.2 U Taq
polymerase (Life Technologies Inc, Carlesbad, California,
USA), and at least 10 ng of DNA in a 20 ml reaction. The
reaction was started with a three minute denaturation at
96 C˚, followed by 30 cycles of 45 seconds of denaturation at
96 C˚, one minute of annealing at temperatures varying
between 52 C˚ and 64 C˚, and a 45 second elongation step at
72 C˚; the programme ended with a five minute elongation
step at 72 C˚ in a PTC-100 or PTC-200 cycler (MJ Research Inc,
Waltham, Massachusetts, USA).
Analysis was carried out using an automated ABI 377 or
ABI 3100 sequencer (Applied Biosystems, Foster City,
California, USA) with a GenescanTM 350ROX size standard
(Applied Biosystems) and the manufacturer’s GenescanH 2.1
software.
Normal samples with two distinctly sized alleles of a
particular marker were termed informative. For all informa-
tive markers, the allelic imbalance factor was calculated
as described by Cawkwell et al.23 LOH was assumed if
the allelic imbalance factor was greater than 1.6 or less
than 0.6. Observed losses were confirmed to exclude induced
LOH.
Immunohistochemistry
Immunohistochemistry (IHC) for p53 and LKB1 was
performed on dewaxed and rehydrated 4 mm sections.
Endogenous peroxidase activity was blocked by 0.3% H2O2
in methanol for 20 minutes. The slides were submerged in
antigen retrieval solution (10mM Tris/1mM EDTA (pH 9.0)
for p53 IHC and 0.01M citrate (pH 6.0) for LKB1 IHC) and
heated for 10 minutes at 120 C˚. After cooling for 10 minutes,
5% normal goat serum in phosphate buffered saline was
applied for 10 minutes. The sections were incubated for one
hour with the primary antibody. Staining for p53 and LKB1
was carried out using the DO-7 and BP53-12 (Neomarkers,
Freemont, California, USA; 1/2000 dilution) and anti-LKB1
(Cell Signaling Technology, Beverly, California, USA; 1/20
dilution) antibodies, respectively. The Powervision+poly–
horseradish peroxidase detection system (ImmunoVision
Technologies, Daly City, California, USA) was used to
visualise the antibody binding sites, with 3,3-diamino-
benzidine as chromogen. Sections were counterstained with
haematoxylin.
Sequence analysis
Table 1 shows the primers used to amplify the STRAD exons
and exon–intron boundaries.
Polymerase chain reaction products were purified using the
Qiagen PCR purification kit (Qiagen Benelux BV, Venlo, the
Netherlands) and the sequencing reaction was performed
using the ABI Big Dye Terminator cycle sequencing kit
(Applied Biosystems) according to the manufacturer’s pro-
tocol. Samples were run on an ABI 3100 genetic analyser and
analysed using Sequence Navigator.
RESULTS
To study the possibility that STRADmay function as a tumour
suppressor gene, LOH analysis was performed on a panel of
42 sporadic adenocarcinomas that consisted of tumours
described in patients with PJS or tumours of which variants
occur in PJS. Adenocarcinomas of the lung, colon, and
stomach have been described in patients with PJS.3 Ovarian
adenocarcinomas were selected because one third of patients
with the rare ovarian sex cord tumour with annular tubules
have PJS.24 To identify losses of the entire chromosome arms
and losses of the known tumour suppressor genes on
chromosome 17, eight microsatellite markers located on
chromosome 17 were used: markers flanking TP53 (17p13.1),
BRCA1 (17q21), and STRAD (17q23.3), in addition to three
other markers on 17q (fig 1). Furthermore, p53 IHC was
performed to substantiate the LOH results for TP53.
As shown in fig 1, 13 of 29 patients showed LOH of the
D17S944 marker near the STRAD locus. All informative
gastric adenocarcinomas showed LOH of the STRAD marker,
whereas only one of the 12 lung adenocarcinomas showed
LOH. Four of the eight ovarian and seven of the 12 colon
adenocarcinomas showed LOH. To investigate whether LOH
near the STRAD gene was specific in these patients, the LOH
status near the TP53 and BRCA1 loci was also assessed.
Three of eight ovarian adenocarcinomas showed retention
of all informative markers on chromosome 17. In contrast,
two cases showed LOH of all informative markers tested. In
the other cases, TP53, BRCA1, or another gene might be
affected except for ovarian adenocarcinoma 7 where STRAD
seemed to be specifically lost.
Two of the 10 gastric adenocarcinomas showed retention of
all chromosome 17 markers and another two showed LOH of
all informative markers on chromosome 17. In most cases
(. 70%) LOH of the TP53 markers was seen. The LOH results
were supported by positive p53 immunohistochemistry
suggestive of a TP53 mutation and loss of functional p53.
Although all informative cases showed LOH for the STRAD
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marker, only one gastric adenocarcinoma (stomach 8) might
have specifically lost STRAD, because all other markers except
for TP53 showed retention in this adenocarcinoma. In this
case, the negative IHC indicated that a remaining TP53 wild-
type allele might be present.
All colon adenocarcinomas showed LOH of one or more
markers on chromosome 17. In three of the 12 cases all
chromosome 17 markers showed LOH. Similar to the gastric
adenocarcinomas, a high proportion (six of 12) of colon
adenocarcinomas showed LOH of TP53. In three cases (colon
6, 7, and 11), the STRAD locus might be lost specifically
because no LOH for TP53 or BRCA1 was identified in these
cases. In cases 10 and 12, the LOH pattern suggested that
genes other than TP53 and BRCA1 were affected.
The lung adenocarcinomas did not show LOH for the
informative markers on chromosome 17. Retention of all
markers was found in two of the 12 cases. Again TP53 LOH
was found frequently (seven of 12 informative cases). Lung
cases 9 and 12 showed LOH of one of the markers around the
TP53 gene; however, no positive IHC indicative of a mutation
in the remaining allele was found. None of the lung
adenocarcinomas showed specific LOH near the STRAD locus;
however, in lung adenocarcinoma case 1 either BRCA1 or
STRAD might be lost.
In total, LOH analysis revealed five of 29 informative cases
with specific LOH near the STRAD locus (ovary 7, stomach 4,
and colon 6, 7, and 11). Mutational analysis of STRAD was
used to investigate whether the second STRAD allele was
inactivated. No mutations were found in the 13 exons or
intron–exon boundaries. However, a single nucleotide poly-
morphism 62279118 C/T was identified in exon 2, 18 base
pairs upstream of the start codon. Cases ovary 7 and colon 6
were heterozygous and a homozygous T allele was found in
cases stomach 4, colon 7, and colon 11, whereas none of the
patients was homozygous for the wild-type C allele.
Although LOH analysis showed LOH near the STRAD locus
in 13 of the 29 sporadic tumours, no STRAD mutations were
found in cases where this region appeared to be specifically
affected. Because STRAD could also be inactivated in other
ways and thus affect the stability or localisation of LKB1, IHC
was carried out on all cases studied.
LKB1 staining was in general relatively weak and varied
between tumours. Tumours of the stomach and colon were
on average more strongly positive than ovarian and lung
adenocarcinomas. Staining was cytoplasmic and occasionally
membranous. No nuclear staining, as would be expected in
the case of dysfunctional STRAD, was observed.
Germline abnormalities of the LKB1 gene have been
reported in about 60% of patients with PJS, with the cause
of the syndrome being unclear in the remaining patients. The
presence of a second disease locus has been proposed, but no
second PJS gene has been identified to date. Because of the
essential function of STRAD in activating LKB1, the question
was raised whether STRAD might be a second PJS gene.
Therefore, STRADmutation analysis was carried out in nine
patients with PJS and one family member where no LKB1
germline mutation had been identified, suggesting that
another gene may have caused the syndrome. Sequence
analysis of exons and exon–intron boundaries revealed no
mutations, although the above described single nucleotide
polymorphism in exon 2 recurred in several patients. Of the
10 PJS family members, five were homozygous for the wild-
type C allele, three were homozygous for the T allele, and two
were heterozygous.
DISCUSSION
The association between loss of epithelial organisation and
malignant progression in mammalian tumours has long been
known, making disorganisation of cell architecture one of the
primary diagnostic features of transformation. The function
Table 1 Primer sequences and polymerase chain reaction conditions for sequencing of 13 exons and exon–intron boundaries
of STRAD
Exon Forward primer Reverse primer Tm ( C˚) MgCl2 (mM)
1 ggtctggcggcggcgcggcagtaaaac cagtccctcctggctctgccaccgattccatctcc 65 1.25
2 ataggtgaagtccagtgctttgaatgg ctgaaaagcagtgtattttggca 52 1.25
3 gtctaaaggctgatagctaatttgttgcggc caatctatagcaattggcaattctaagggcaagtgtaacc 65 2.5
4 ttgctgttctgaatgtgggtgtgtcttctg ggctgttgcatggagatgacttcttgtggaagtttgtgtg 52 1.25
5 cctcgtgggtctgaattaccaccttcacccca ccaggggctgctgcagctttctcagcag 65 1.25
6 ccttttgttgttcttgtccttgcgtatggc gagtgtgtcacatggagggaggg 65 1.25
7+8 gctgccatctttgtgttgagcggc ggcggcctttcccatgattacag 65 1.25
9 gccaggtggagtgtgtgaagacca gggagccttcaggcattgcc 65 1.25
10 ctctctttagttctaccc gagtagctctcacactcagg 52 2.5
11 ccgctacagcccaggtcc cttcgggagagcagagggtg 65 2.5
12+13 ggctgaggcataagtggcagga ggatgcagaggccacccagag 65 1.25
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Figure 1 Loss of heterozygosity (LOH) results for eight microsatellite markers on chromosome 17, including those near the STRAD, BRCA1, and TP53
loci, in addition to the results for p53 immunohistochemistry (IHC) for 42 sporadic ovarian, gastric, colon, and lung adenocarcinomas. Dark circles,
LOH; open circles, retention; 2, not informative; +, positive staining; and IC, inconclusive.
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of LKB1 in regulating cell polarity should provide insight into
a possible mechanism of tumour formation in patients with
PJS. Loss of both LKB1 alleles in PJS tumours may lead to a
disruption of polarity, ultimately resulting in transformation
and tumour growth. LKB1 functions as a tumour suppressor
gene in PJS and LKB1 aberrations have also been described in
sporadic tumours. One third of sporadic lung adenocarcino-
mas showed inactivation of LKB1,7 and this was also seen to a
lesser extent in sporadic biliary and pancreatic carcinomas.8
In addition, somatic mutations of LKB1 have been reported in
malignant melanoma.9 The link between LKB1 and cell
polarity through STRAD raised the question of whether
STRAD might also be involved in sporadic tumour formation.
Because this involvement may be tumour specific, we
selected four sporadic tumour types of which subtypes occur
in patients with PJS to study LOH of STRAD and LKB1
expression.
To eliminate cases that show LOH of the entire chromo-
some or chromosome arm, in addition to LOH of the known
tumour suppressor genes on chromosome 17, TP53 and
BRCA1, the LOH status of eight microsatellite markers was
assessed. LOH of the STRAD marker was found in 13 of 29
informative cases. Ten of the adenocarcinomas showed no
LOH of the informative markers on chromosome 17 and
another seven cases showed LOH of all informative markers
on chromosome 17. LOH of chromosome 17 was most
prominently present in the group of colon adenocarcinomas
and least prominent in lung adenocarcinomas.
LOH near the TP53 locus was found in most gastric, colon,
and lung adenocarcinomas (50–70%), whereas only two of
the eight ovarian adenocarcinomas showed LOH. These
results indicate that loss of TP53 is indeed a common event
in tumour formation, as has been described previously for
these tumours. LOH of TP53 was reported in approximately
60% of gastric adenocarcinomas.25 In lung cancer it has been
shown that the short arm of chromosome 17 is one of the
most frequently affected chromosomal regions, and there is
solid evidence that the TP53 gene is a target for these
deletions.26 In colon carcinomas loss of chromosome 17p,
including the TP53 locus, was described as a late event in the
adenoma–carcinoma sequence.27 In ovarian tumours, LOH at
the TP53 locus has been described in up to 81% of cases.28 29 In
our study, we found LOH of TP53 in two of eight cases,
indicating that in ovarian adenocarcinomas LOH of other
genes may be more important than LOH at the TP53 locus.
‘‘There are no indications that expression of the STRAD
protein is aberrant in these sporadic adenocarcinomas,
despite the high percentage of loss of heterozygosity at
17q’’
In ovarian carcinomas, inactivation of BRCA1 may occur
more frequently. LOH of BRCA1 has been described in up to
50% of ovarian tumours.28 30 In our study, only one of eight
ovarian adenocarcinomas showed LOH of both BRCA1
markers. In addition, only one case with LOH of BRCA1
was identified in the colon and lung adenocarcinomas in our
study. LOH of the 17q21 region was reported in approxi-
mately 50% of colon and lung adenocarcinomas.31 32 Although
in gastric adenocarcinomas a relatively high percentage of
LOH at 17q21 was described, no BRCA1 mutations were
found, which is indicative of the presence of another tumour
suppressor gene.33
According to Knudson’s two hit theory, tumour suppressor
genes are inactivated by a recessive mutation in one allele
and loss of the other wild-type allele.34 Frequent LOH is
consequently considered to be an indicator of gene inactiva-
tion. Specific LOH of STRAD was found in five of our cases.
Mutational analysis did not identify mutations in the exons
or intron–exon boundaries. Because the possibility remains
that STRADmay be inactivated in another way, and this could
result in the aberrant localisation of LKB1, LKB1 immuno-
histochemical staining was performed. However, no nuclear
staining indicative of dysfunctional STRAD was observed.
Based on these results, we concluded that there are no
indications that expression of the STRAD protein is aberrant
in these sporadic adenocarcinomas, despite the high percen-
tage of LOH at 17q. Several reports have already suggested
that other tumour suppressor genes may be located at
chromosome 17q in the tumours studied. Alterations in
chromosome segment 17q23, and marker D17S794 in
particular, tended to be associated with early stage lung
adenocarcinoma and longer survival.35 Furthermore, a puta-
tive tumour suppressor gene locus was identified distally
from the STRAD locus at 17q25, with LOH ranging from 25%
to 70% of studied ovarian adenocarcinomas.36 At chromoso-
mal location 17q21.3, the metastasis suppressor NM23-H1 has
been suggested to play a role in colon cancer progression and
metastasis.37 However, LOH of NM23-H1 was found in only
14% of gastric carcinomas, indicating that inactivation is not
essential in gastric cancer.38
Based on our results, STRAD does not seem to be essential
for tumour formation in the sporadic tumour types studied.
In patients with PJS this may be different, because a link
with LKB1 has already been established. The essential role of
STRAD in LKB1 activation in the establishment of cell
polarity suggests that defects in the STRAD gene have the
same effects as loss of LKB1 function. However, despite its
important role for the function of LKB1, no germline
mutations were detected in the patients with PJS studied,
therefore excluding STRAD as a potential second PJS gene.
Although alternative mechanisms of inactivation such as
hypermethylation, exon deletions, or intronic mutations
cannot be excluded, it does not seem likely that loss of
STRAD function can cause PJS. A final possibility of germline
hemi-allelic methylation, as seen for MLH1 in some patients
with early onset colorectal cancer and high microsatellite
instability,39–41 seems to be an unlikely explanation for the
involvement of STRAD in PJS and sporadic cancers. Even if
this is the case in patients with PJS and known LKB1
germline mutations, it is unlikely that hemi-allelic methyla-
tion, which has been found only sporadically thus far,
accounts for the patients with PJS without LKB1 germline
mutation.
During the course of our study the search for mutations in
the LKB 1 gene was continued using a special procedure for
large deletions in unresolved Dutch families affected by PJS.
This revealed new intron deletions that result in skipping of
multiple exons in the LKB1 mRNA. Thus, at present 15 of 19
Dutch families affected by PJS have a mutation in the LKB1
gene (AM Westerman et al, unpublished data, 2005).
Although the proportion of patients with PGS not linked to
Take home messages
N Although there was a high occurrence of loss of
heterozygosity in the STRAD region at 17q in patients
with Peutz-Jeghers syndrome (PJS), inactivation of the
STRAD gene is not essential in the sporadic adeno-
carcinomas studied in these patients, although it is
possible that STRAD may be inactivated in different
ways
N In addition, no evidence was found for the hypothesis
that STRAD is the second PJS susceptibility gene
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the LKB1 gene may be lower than previously estimated, other
LKB1 interacting or activating proteins remain possible
candidates for a second PJS gene.
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